Compare · RGNX vs VYGR
RGNX vs VYGR
Side-by-side comparison of REGENXBIO Inc. (RGNX) and Voyager Therapeutics Inc. (VYGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RGNX and VYGR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RGNX is the larger of the two at $327.8M, about 1.6x VYGR ($207.2M).
- Over the past year, RGNX is down 35.6% and VYGR is down 0.9% - VYGR leads by 34.7 points.
- RGNX has been more active in the news (13 items in the past 4 weeks vs 3 for VYGR).
- RGNX has more recent analyst coverage (22 ratings vs 13 for VYGR).
- Company
- REGENXBIO Inc.
- Voyager Therapeutics Inc.
- Price
- $6.32+3.10%
- $3.42+1.48%
- Market cap
- $327.8M
- $207.2M
- 1M return
- -40.21%
- -15.22%
- 1Y return
- -35.58%
- -0.87%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2015
- News (4w)
- 13
- 3
- Recent ratings
- 22
- 13
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Voyager Therapeutics Inc.
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest RGNX
- Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.
- SEC Form SC TO-I filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- Director Tasse Daniel was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Stump David C was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Zachary Jennifer was granted 9,807 shares, increasing direct ownership by 44% to 31,871 units (SEC Form 4)
- Director Mills Kenneth T. was granted 9,807 shares, increasing direct ownership by 2% to 495,925 units (SEC Form 4)
- Director Migausky George V was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Karabelas Argeris N was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Glucksmann Alexandra was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
Latest VYGR
- SEC Form 8-K filed by Voyager Therapeutics Inc.
- Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
- New insider Quinlan Amy claimed ownership of 36,749 shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.
- A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
- Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
- Voyager Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Voyager Therapeutics Inc.
- Voyager Reports First Quarter 2026 Financial and Operating Results